19 December 2025
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Alison Haggerty Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Jie Lin Nai | Latham & Watkins LLP | Associate | Capital Markets | New York |
| Elana Cates | Latham & Watkins LLP | Associate | Capital Markets | New York |
Stated terms
- Stated value
- USD 50m (US$50 million)
- What the figure measures
- Issue size
- Client
- Latham & WatkinsUnderwriters
- Counterparties
- Kalaris Therapeutics, Inc. (Issuer)
institutional accredited investors (Investor)